These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31672614)

  • 21. Pharmacology and pharmacokinetics of fosphenytoin.
    Browne TR; Kugler AR; Eldon MA
    Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD.
    Narisawa S; Stella VJ
    J Pharm Sci; 1998 Aug; 87(8):926-30. PubMed ID: 9687335
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Correa L; de Carvalho Meirelles G; Balestrin L; de Souza PO; Moreira JCF; Schuh RS; Bidone J; von Poser GL; Teixeira HF
    Photochem Photobiol Sci; 2020 Oct; 19(10):1460-1469. PubMed ID: 33026028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Update on Nanoemulgel as Topical Drug Delivery System.
    Choudhury H; Gorain B; Pandey M; Chatterjee LA; Sengupta P; Das A; Molugulu N; Kesharwani P
    J Pharm Sci; 2017 Jul; 106(7):1736-1751. PubMed ID: 28412398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probabilistic approach to the establishment of maximal content limits of impurities in drug formulations: the case of parenteral diphenylhydantoic acid.
    Manca D; Walker RM; Krishna G; Graziano MJ; Kropko ML
    Regul Toxicol Pharmacol; 1999 Feb; 29(1):1-14. PubMed ID: 10051414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous administration of fosphenytoin: options for the management of seizures.
    Ramsay RE; DeToledo J
    Neurology; 1996 Jun; 46(6 Suppl 1):S17-9. PubMed ID: 8649609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular use of fosphenytoin: an overview.
    Uthman BM; Wilder BJ; Ramsay RE
    Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
    Yang M; Gu Y; Yang D; Tang X; Liu J
    J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation development of novel in situ nanoemulgel (NEG) of ketoprofen for the treatment of periodontitis.
    Srivastava M; Kohli K; Ali M
    Drug Deliv; 2016; 23(1):154-66. PubMed ID: 24786482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation and Evaluation of Thermoreversible In Situ Nasal Gels Containing Mometasone Furoate for Allergic Rhinitis.
    Altuntaş E; Yener G
    AAPS PharmSciTech; 2017 Oct; 18(7):2673-2682. PubMed ID: 28281209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).
    Atef E; Belmonte AA
    Eur J Pharm Sci; 2008 Nov; 35(4):257-63. PubMed ID: 18706499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
    Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
    Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
    Burstein AH; Cox DS; Mistry B; Eddington ND
    Epilepsy Res; 1999 Apr; 34(2-3):129-33. PubMed ID: 10210027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin.
    Löscher W; Reissmüller E; Ebert U
    Epilepsy Res; 1998 Mar; 30(1):69-76. PubMed ID: 9551846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabrication, Characterization, In vitro Evaluation of Solid Lipid Nanoemulsion of Flunarizine dihydrochloride for Nasal Delivery.
    Newton MJ; Harjot K
    Antiinflamm Antiallergy Agents Med Chem; 2017; 15(3):204-220. PubMed ID: 27993106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of nanoemulsion gel drug delivery systems of cetirizine; factorial optimisation of composition,
    Kassem MA; Ghalwash MM; Abdou EM
    J Microencapsul; 2020 Sep; 37(6):413-430. PubMed ID: 32421463
    [No Abstract]   [Full Text] [Related]  

  • 38. Development, optimization and in vitro evaluation of norcantharidin loadedself-nanoemulsifying drug delivery systems (NCTD-SNEDDS).
    Zeng L; Zhang Y
    Pharm Dev Technol; 2017 May; 22(3):399-408. PubMed ID: 27487261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fosphenytoin in infants.
    Takeoka M; Krishnamoorthy KS; Soman TB; Caviness VS
    J Child Neurol; 1998 Nov; 13(11):537-40. PubMed ID: 9853645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of Olive Oil-Based Nanoemulsion Preparation for Intravenous Drug Delivery.
    Karami Z; Khoshkam M; Hamidi M
    Drug Res (Stuttg); 2019 May; 69(5):256-264. PubMed ID: 30086568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.